Novel RNA Interference (RNAi)-Based Nanomedicines for Treating Viral Infections - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 206

Table 7.1 Antiviral RNAi-based therapeutics

Virus Drug Name RNAi Type Delivery Method Stage Reference

HBV N/A shRNA Hydrodynamic Tail vein Murine Model [86]

N/A shRNA Adeno-associated virus Murine Model [45]

N/A siRNA SNALPs Murine Model [91, 92]

N/A siRNA Apo A-I cationic nanoparticle Murine Model [65]

N/A siRNA Single-chain antibody Murine Model [116]

HPV N/A shRNA Ex vivo lentiviral transduction Murine Model [47]

N/A siRNA Intratumoral Murine Model [126]

HSV-2 N/A siRNA Intravaginal microbiocide Murine Model [98]

N/A siRNA Cholesterol Murine Model [124]

WNV N/A siRNA Hydrodynamic tail vein Murine Model [5]

JEV/
WNV

N/A shRNA Lentivirus pseudotyped with RVG

(i.c.)

Murine Model [71]

N/A siRNA i.c. Murine Model [71]

N/A siRNA i.v. complexed to RVG Murine Model [72]

YFV N/A shRNA i.c. Murine Model [97]

HCV ISIS 14803 ASO i.v Phase II discontinued [87]

Miravirsen ASO s.c. Phase II ongoing [22]